  == Issues about the scheduling by the FDA ==  While the explanation of the current delay in market introduction of tapentadol is significant to an extent, it needs to be sourced and verified in my opinion for such a large part of the article. There is too much speculations which are supposely an issue of current negotiations between Johnson&Johnson;/Gruenenthal and the FDA; as of now, in my opinion, some of these speculations are not verifiable since they are subject of an ongoing confident debates. Maybe it should be reduced to verifiable facts and expanded over time, as the positions and results of these discussions become clear and public. Any ideas?   